Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Digital Realty Expands Talent Development Opportunities for Operations Workforce Through Partnership with DCD Academy
-
Washington, DC, May 05, 2026 (GLOBE NEWSWIRE) -- Today (May 5, 2026), on World Asthma Day, the Asthma and Allergy Foundation of America (AAFA), along with the American Academy of Allergy, Asthma,...
-
Key findings from the DME AWARE initiative highlight the importance of non-invasive treatment options for early intervention in diabetic macular edema (DME) managementOculis is on track to report...
-
ZUG, Switzerland, May 05, 2026 (GLOBE NEWSWIRE) -- Key findings from the DME AWARE initiative highlight the importance of non-invasive treatment options for early intervention in diabetic macular...
-
What 2026 buyers should verify: Halo Care Skin Tag Remover claims, ingredients, pricing, refund terms, and dermatologist guidance.
-
-- Total revenue of $177 million, reflecting increase of 5 percent over first quarter 2025 driven by growth across commercial portfolio, including EXPAREL volume growth of 7 percent -- -- Completed...
-
Highlights Aligned with the FDA in two Positive Type C meetings supporting key elements of the planned Phase 3 program for ATH434 in MSAAdvancing ATH434 toward pivotal Phase 3 program; on track for...
-
KT-621 (STAT6) parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late 2027, respectively FDA granted Fast Track designation to...
-
Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026
New real-world data confirm Vabysmo’s potent retinal drying in nAMD and DMEKey data for Susvimo demonstrate its potential to provide lasting disease control through continuous delivery, while reducing...
-
NEW YORK, April 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that its pivotal...